Business context and reporting period
Agape ATP Corp. filed this Form 10-K for the fiscal year ended June 30, 2018 (with June 30, 2017 comparatives). The supplied “2017 Q4” period label does not match the filing’s annual reporting period. The company sells health and wellness products and plans to provide related advisory services, initially in Malaysia. It reported product revenue during the year but described much of its operating model—including hiring salespeople, securing office and storage space, and setting service prices—as still under development.
Financial results and position
| Metric (US$ unless stated) | FY2018 | FY2017 |
|---|---|---|
| Revenue | $487,005 | $0 |
| Cost of revenue | $441,409 | $0 |
| Gross profit / margin | $45,596 / 9.4% | — |
| Net loss | $130,274 | $75,362 |
| Operating cash flow | $(347,977) | $(100,262) |
| Investing cash flow | $(1,362,490) | $0 |
| Financing cash flow | $2,930,267 | $2,413,000 |
| Cash and cash equivalents at year-end | $3,531,255 | $2,312,748 |
| Total assets | $5,128,531 | $2,312,748 |
| Total liabilities | $29,750 | $8,100 |
| Working capital | $3,766,446 | Not clearly stated |
| Stockholders’ equity | $5,098,781 | $2,304,648 |
FY2018 selling, general and administrative expenses were $265,682 and other operating expenses were $14,000. The company also recorded $1,698 realized and $134,392 unrealized foreign-exchange gains, $3,211 other income, and a $30,155 share of loss from its investee. The reported net loss widened year over year despite those foreign-exchange gains. Cash equivalents included $1,046,706 cash and $2,484,549 in time deposits. Current liabilities were limited and included $3,922 due to a director; the filing reports no material off-balance-sheet arrangements.
Material changes versus FY2017
- Revenue began in FY2018, but gross margin was about 9.4%; the filing attributes revenue mainly to health-product sales.
- Administrative and operating expenses increased to $279,682 from $75,362, which management attributed primarily to filing and professional fees.
- Operating cash use increased, while investing outflows of $1,362,490 reflected an investment in an investee and marketable securities.
- Financing was principally from share issuance. The company completed an IPO at $1.00 per share, raising $2,925,500, and reported 376,275,500 shares outstanding at year-end.
- The company reported an $862,490 investment in Unreserved Sdn Bhd, carried at $832,335 after its share of investee losses, and a $500,000 investment in Greenpro Capital Corp. securities.
Outlook, risks, contingencies and unusual items
- Outlook: Management plans to build a Malaysian sales operation and considers future expansion into Thailand, Indonesia and Taiwan, but provides no specific timeline, revenue guidance or budget. It says operations and planned growth may require additional capital; financing may not be available when needed.
- Execution and supply risks: The products are third-party manufactured and rebranded; the company disclosed no supplier contracts. It had not yet hired salespeople or secured storage space, and service pricing was not finalized. A supplier discontinuing a product could require replacement sourcing.
- Customer and vendor concentration: One customer accounted for 100% of FY2018 revenue, and one vendor accounted for 100% of purchases. The sole customer, Agape S.E.A. Sdn Bhd, was directed by the company’s CEO; the filing also identifies director connections to other counterparties.
- Related parties and governance: Greenpro, a 4.7% shareholder, provided services; the company disclosed $214,000 of professional fees in FY2018 and a $500,000 investment in Greenpro securities. The CEO controlled 83.74% of voting shares. The company had no independent director, audit committee, or audit committee financial expert, and had not adopted a formal code of ethics or formal related-party transaction approval procedures.
- Controls: Management concluded internal control over financial reporting was ineffective and identified material weaknesses involving missing written accounting policies and procedures, inadequate segregation of duties, and risk assessment. The filing says those weaknesses contributed to failure to properly record or timely disclose a private placement. Remediation was planned, but the stated target date (“end of fiscal year 2017”) appears inconsistent with this FY2018 report and should be checked.
- Product and regulatory claims: The filing says required Malaysian product authorizations had been obtained, but states that efficacy references are based on client testimonials. Product availability, regulatory compliance and the substantiation of health-related claims remain important diligence items.
- Market and currency: No public market or trading history existed for the common stock, and penny-stock rules may constrain trading. The company also flags exchange-rate exposure. It reported no pending legal proceedings expected to have a material adverse effect.
The independent auditor gave an unqualified opinion on the financial statements; the auditor did not audit internal-control effectiveness. No formal financial guidance was provided.
Important facts for investors to verify
- Confirm the customer and vendor identities, the related-party relationships, and whether the 100% concentration continued after year-end.
- Review the economics and terms of the Unreserved and Greenpro investments, including valuation, liquidity, conflicts and any subsequent changes.
- Reconcile the reported operating results, particularly the large unrealized foreign-exchange gain, gross margin, and the differing loss figures described in the MD&A and financial statements.
- Check progress in hiring, establishing facilities, contracting with suppliers, and converting product sales into recurring and diversified revenue.
- Assess remediation of material weaknesses, the apparent remediation-date inconsistency, and whether accounting controls and related-party oversight have improved.
- Verify current cash availability, time-deposit restrictions, ongoing cash burn, capital needs, share count and any subsequent financing or dilution.